Phenylbutazone, often referred to as "bute", is a nonsteroidal anti-inflammatory drug (NSAID) for the short-term treatment of pain and fever in animals. Phenylbutazone. Clinical data. Trade names. Butazolidine. As a nonselective cyclooxygenase inhibitor, phenylbutazone reduces prostaglandin synthesis to produce analgesic, antipyretic and anti-inflammatory effects; it is rapidly absorbed after oral administration and undergoes hepatic metabolism with formation of oxyphenbutazone and other hydroxylated metabolites, which can contribute to both efficacy and toxicity. In veterinary practice the compound is formulated as sodium salts, bolus or paste preparations for equine and other large animal use; therapeutic monitoring, awareness of drug interactions with diuretics and ACE inhibitors, and species-specific pharmacokinetics are important components of clinical use and risk management.
Parent: Phenylbutazone
Parent: Phenylbutazone
Parent: Phenylbutazone
Parent: Phenylbutazone
Parent: Phenylbutazone
Parent: Phenylbutazone
Quality control for phenylbutazone active pharmaceutical ingredient typically monitors both specified related compounds and total impurities by validated HPLC methods; common related substances include oxyphenbutazone (a primary metabolite and potential degradation product), mono- and di-hydroxylated phenylbutazone isomers and trace synthetic byproducts from batch manufacture. Typical specification limits used in pharmacopeial-style quality systems are assay not less than 98.0 percent, individual related compound limits of 0.5 percent or less and total related compounds typically controlled to 2.0 percent or less, with tighter limits applied for any impurity flagged as potentially genotoxic (for example genotoxic impurities would be controlled to parts-per-million levels). Residual solvents and heavy metals are addressed by corresponding limits (for example ICH Q3C and Q3D guidelines) and stability testing defines specification-appropriate degradation allowances under accelerated and long-term conditions.
Phenylbutazone is used in veterinary medicine for short-term relief of musculoskeletal pain, inflammation and fever, most commonly in horses and other large animals, and is selected when potent analgesia and anti-inflammatory action are required under veterinary supervision.
In horses phenylbutazone reduces inflammation and pain associated with laminitis, musculoskeletal injury and arthritis by inhibiting prostaglandin synthesis; therapeutic benefit must be balanced against risks such as gastrointestinal ulceration, right dorsal colitis, renal impairment and hematologic adverse effects, so clinical monitoring is essential.
Phenylbutazone acts as a nonselective inhibitor of cyclooxygenase enzymes, COX-1 and COX-2, decreasing the conversion of arachidonic acid to prostaglandins which mediate pain, inflammation and fever; metabolites such as oxyphenbutazone contribute to the pharmacologic and toxicologic profile.
The principal adverse effects include gastrointestinal ulceration and bleeding, renal toxicity and hematologic disorders such as bone marrow suppression or aplastic anemia in susceptible animals; in horses, right dorsal colitis and renal compromise are among the most clinically important safety concerns and require prompt veterinary management.
